Fruquintinib Plus Camrelizumab and Capecitabine as Salvage Therapy After Progression on FOLFOXIRI-based First-line Treatment in Patients With Unresectable/Metastatic Colorectal Cancer

NCT06148402 · clinicaltrials.gov ↗

PHASE2

Phase

RECRUITING

Status

30

Enrollment

OTHER

Sponsor class

Conditions

Unresectable/Metastatic Colorectal Cancer

Interventions

DRUG: Fruquintinib plus camrelizumab and capecitabine

Sponsor

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University